Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

 Key Statistics

Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO

 Company News
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014 10:05:54 AM
FDA Approves Baxter International, Inc. (BAX), Halozyme Therapeutics, Inc. (HALO)'s HYQVIA 9/15/2014 6:15:03 AM
Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation 9/3/2014 4:29:03 PM
Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation 9/3/2014 10:27:41 AM
Halozyme Therapeutics, Inc. (HALO) Reports Second Quarter 2014 Financial Results 8/12/2014 8:42:34 AM
Halozyme Therapeutics, Inc. (HALO) To Host second Quarter 2014 Financial Results Conference Call 8/5/2014 7:22:01 AM
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014 1:47:13 PM
Roche (RHHBY)'s Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme Therapeutics, Inc. (HALO) 6/25/2014 6:47:57 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The JMP Securities 2014 Healthcare Conference 6/18/2014 10:44:22 AM
Halozyme Therapeutics, Inc. (HALO) Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions 6/16/2014 7:52:45 AM